Biotechnological Production of Vitamins by Shrikant A. Survase et al.
ISSN 1330-9862 review
(FTB-1658)
Biotechnological Production of Vitamins
Shrikant A. Survase, Ishwar B. Bajaj and Rekha S. Singhal*
Food and Fermentation Technology Department, Institute of Chemical Technology,
University of Mumbai, Matunga, Mumbai 400019, India
Received: December 20, 2005
Accepted: March 20, 2006
Summary
Vitamins are defined as essential micronutrients that are required in trace quantity
and cannot be synthesized by mammals. Apart from their in vivo nutritional and physio-
logical roles as growth factors for men, animals, plants and microorganisms, vitamins are
now being increasingly introduced as food/feed additives, as medical-therapeutic agents,
as health aids, and also as technical aids. Production of vitamins by chemical synthesis, or
extraction from their known sources has serious disadvantages. This led to an increased in-
terest in substituting these processes with biotechnological processes. For several of these
compounds microbiological and algal processes exist, or are rapidly emerging. Different
methods like media optimization, mutation and screening, genetic engineering and bioca-
talyst conversion have been used for improvement of the production of vitamins. The sur-
vey describes the current state of vitamin production by biotechnological processes and
their significance, as compared to the existing chemical processes.
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Introduction
Vitamins, defined as essential micronutrients re-
quired in trace quantities that cannot be synthesized by
mammals, are essential for metabolism of all living or-
ganisms and are synthesized by microorganisms or plants.
Apart from their in vivo nutritional-physiological roles
as growth factors for men, animals, plants and microor-
ganisms, vitamins are now increasingly being introduced
as food/feed additives, as medical-therapeutic agents,
as health aids, and also as technical aids. Today, many
processed foods, feeds, pharmaceuticals, cosmetics, and
chemicals contain extraneously added vitamins or vita-
min–related compounds.
Most of the vitamins are now industrially produced
and widely used in foods, pharmaceuticals and cosme-
tics. Presently, few of the vitamins are exclusively pro-
duced via chemical synthesis, while a few others are
produced either by chemical synthesis or via extraction
processes. These processes are energy-intensive, and also
suffer from high cost of waste disposal. Furthermore,
these processes have growing consumer consciousness
with regard to food additive safety. This has led to in-
creased interest in substituting these processes with bio-
technological processes. Consequently, biotechnological
processes for the production of most of these compounds
are rapidly emerging and some are already competing
with the existing chemical processes. A list of vitamins
produced by biotechnological methods is summarized
in Table 1.
Fat-Soluble Vitamins
Of the four fat-soluble vitamins, viz. vitamins A, D,
E and K, some success has been obtained with biotech-
nological production of vitamins E and K. These are dis-
cussed below:
Vitamin E (a-tocopherol)
Vitamin E comprises a group of lipid-soluble com-
pounds, among which a-tocopherol is the most abundant
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and has the highest antioxidant activity in vivo. In nature,
only photosynthetic organisms are capable of producing
a-tocopherol. In humans, a-tocopherol is believed to play
a major role in prevention of light induced pathologies of
the skin, eyes and degenerative disorders such as athero-
sclerosis, cardiovascular diseases and cancer. Industrial
application of a-tocopherol includes its use in preserva-
tion of food, in cosmetics and sunscreens (8).
Currently a-tocopherol is obtained by chemical syn-
thesis and by extraction from vegetable oils. Extraction
from oils is not efficient, as these typically contain low
levels of a-tocopherol. Unlike other vitamins, synthetic
a-tocopherol is not identical to the form that occurs in
nature. The synthetic form is a mixture of eight stereo-
isomers collectively known as all-rac-alpha-tocopherol,
consisting of four 2R- and four 2S-isomers. Studies with
animals and humans have demonstrated that the 2R-iso-
mers are preferentially retained; therefore when admin-
istered in equal amounts, the bioavailability of natural
with respect to synthetic a-tocopherol is 2:1. Further-
more, growing consumer consciousness with regard to
food additive safety has led to increased interest in sub-
stituting synthetic antioxidant with natural one, which
in turn has encouraged research on alternative sources
of natural antioxidant including a-tocopherol.
Several strains of freshwater microalgae Euglena gra-
cilis Z. (1) and marine microalgae Dunaliella tertiolecta (9)
produce a-tocopherol in concentrations higher than con-
ventional foods traditionally considered as rich sources
of the vitamin. Optimization studies for a-tocopherol pro-
duction have been done with E. gracilis Z, which involved
modification of culture conditions, two-step culture and
screening of favourable substrates that enhance not only
growth but also production of a-tocopherol. It was ob-
served that high cell density caused a decrease in light
penetration to each cell, decreasing photosynthetic activ-
ity. This in turn decreased the aerobic conditions and in-
creased the vitamin E content. Furthermore, consump-
tion of oxygen and glucose by respiration would en-
hance heterotrophic metabolism. The vitamin E content
of the high-density photoheterotrophically grown cells
by fed-batch culture reached 1.21 mg/g dry cell mass.
Simultaneous production of high amounts of b-caro-
tene, vitamin C and vitamin E has also been successfully
demonstrated by E. gracilis Z. using two-step culture. In
the first step of the batch culture, E. gracilis Z. was photo-
heterotrophically cultivated in modified Oda and modi-
fied Hunter media at high light intensity. When the cells
reached late exponential phase, they were separated,
washed and resuspended in the same volume of Cramer
and Mayers (CM) medium for the second step of culti-
vation. The two-step cultures using high cell densities
gave high productivity of antioxidant vitamins (1,10).
Carballo-Cardenas et al. (10) studied a-tocopherol
production with Dunaliella tertiolecta and Tetraselmis sue-
cica in order to assess the effect of light availability. An
inverse relation between light availability and a-toco-
pherol content of Dunaliella tertiolecta was observed. In
addition, diminished light availability did not limit a-to-
copherol in Dunaliella tertiolecta and Tetraselmis suecica.
No correlation between chlorophyll-a (Chl-a) and a-to-
copherol production of these species was observed. The
addition of nitrate and phosphate to a culture of Tetrasel-
mis suecica resulted in an increase of Chl-a and a-toco-
pherol, demonstrating that nutrient composition can be
used as a tool to improve a-tocopherol productivity.
Menaquinone (vitamin K2)
There are two naturally occurring forms of vitamin
K, vitamin K1 and K2. Vitamin K1 (phylloquinone) is
produced in plants. Vitamin K2 (menaquinone, MK) is
primarily synthesized by bacteria, and refers to a series
of naphthoquinones having a variable side chain between
4 and 13 isoprene units in length. The compounds in the
series are referred to as MK-n, where n denotes the num-
ber of isoprene units (Fig. 1) (11).
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Enzyme/ microorganism used Method
Fat-soluble vitamins
Vitamin E (a-tocopherol) Freshwater microalgae Euglena gracilis Fermentative production from glucose (1)
Vitamin K2 Mutated strain of Bacillus subtilis Fermentation using soybean extract (2)
Water-soluble vitamins
Ascorbic acid (vitamin C) 2,5-diketo-D-gluconic acid reductase
Cynobacterium sp.
Fermentative process to 2-keto-L-gulonic
acid followed by chemical conversion to
L-ascorbic acid
(3,4)
Biotin Fermentation (Serratia marcescens)
Multiple enzyme system (Bacillus
sphaericus)
Fermentative production from glucose
by genetically engineered bacterium
Conversion from diaminopimelic acid
using the biotin biosynthetic enzyme
system of mutant of (Bacillus sphaericus)
(5)
Riboflavin Fermentation (Eremothecium ashbyii,
Ashbya gossypii, Bacillus sp., etc.)
Fermentative production from glucose (6)
Vitamin B12 Fermentation (Propionibacterium
shermanii, Pseudomonas denitrificans)
Fermentative production from glucose (7)
Vitamin K is an essential cofactor for the post-trans-
lational conversion of glutamic acid residues of specific
proteins in blood and bone to g-carboxyglutamic acid.
Several comparative studies of the ability of MK homo-
logues to promote the g-carboxylation of Glu proteins in
liver are reported. Homologues MK-4, MK-5 and MK-6
are shown to be highly effective in improving hypopro-
thrombinaemia induced by an anticoagulant in vitamin
K deficient rats (12). On the other hand MK-7 has a
much higher effect on the decreasing PIVKA-II (protein
induced by vitamin K absence or anticoagulant-II) levels
than MK-4 (13).
Various researchers have extensively studied the me-
chanism of menaquinone formation in Bacillus subtilis
(14,15). Tani and Taguchi (16) have reported that as
much as 182 mg/L MK was produced using detergent
supplement culture and a mutant of Flavabacterium. On
the other hand, lactic acid bacteria are reported to pro-
duce menaquinones with the yield of 29–123 mg/L MK-7,
MK-8, MK-9 and MK-10 (17). In fermented soybeans,
natto, Bacillus subtilis produces menaquinones, the major
component being MK-7 and the minor one being MK-6.
Sato et al. (2) obtained a diphenylamine-resistant mutant
strain D2000-41 from Bacillus subtilis strain MH-1 that
was isolated from natto. The mutant strain exhibited in-
creased production of MK-7. They also found static cul-
tures to produce higher amounts of MK-7, as compared
to agitated and aerated cultures. Sumi (18) studied pro-
duction of vitamin K by the fermentation of okara with
seven different natto bacilli. While the MK-4 concentra-
tions remained unchanged during okara fermentation,
that of MK-7 markedly increased during the course of
fermentation. The highest production rate of 36.6 mg/g
was seen in the Chinese natto strain (Unnan SL-001) fol-
lowed by (in mg/g of okara-natto wet mass): 14.2 in
Naruse, 11.9 in Asahi, 6.8 in Takahashi, 1.9 in Miyagino
(natto bacilli for food production), and 5.2 in Nitto and
1.9 in Meguro (natto bacilli for medicine) after incubation
for 4 days at 37 °C. The water-soluble vitamin K was
isolated as a dark yellow powder by DEAE Sepharose
chromatography and membrane filter fractionations.
Water-Soluble Vitamins
Riboflavin
Riboflavin, or vitamin B2, is used for human nutri-
tion and therapy and as an animal feed additive. Its defi-
ciency in humans is correlated with loss of hair, inflam-
mation of skin, vision deterioration, and growth failure.
This vitamin has also been found to be successful in
treatment of migraine (19) and malaria (20). Riboflavin
has been produced commercially by chemical synthesis,
by fermentation and by a combination of fermentation
and chemical synthesis. Recently, fermentation route has
been widely used as it produces the vitamin in a single
step, resulting in substantial cost savings. In contrast,
chemical processes are multistage, and incur a lot of
cost. Most of the producers like BASF, Roche, ADM/
Aventis, Hubei Guangji prefer fermentative production
of riboflavin over chemical process (6).
Although bacteria (Clostridium sp.) and yeasts (Can-
dida sp.) are good producers, two closely related asco-
mycete fungi, Eremothecium ashbyii and Ashbya gossypii,
are considered the best riboflavin producers (21). Ashbya
gossypii produces 40 000 times more vitamin than it needs
for its own growth. Ferrous ion inhibits riboflavin pro-
duction by low and moderate overproducers, such as Clo-
stridia and Candida. The ability of Eremothecium ashbyii
and Ashbya gossypii to repress the effect of iron is re-
sponsible for overproduction of riboflavin. In normal
microorganisms, it appears that iron represses almost all
the biosynthetic enzymes involved in riboflavin produc-
tion, whereas riboflavin or its derivative inhibit the first
enzyme of the pathway, guanosine 5’-triphosphate (GTP)
cyclohydrolase II (22).
Fermentative production of riboflavin
Fermentative production of riboflavin is carried out
in submerged culture. Factors such as the microbial strain,
carbon source, minerals, and pH affect the fermentative
production of riboflavin. Various researchers have opti-
mized these factors to obtain the maximum yield of ri-
boflavin.
Fermentation using Ashbya gossypii. Different car-
bon sources like palm oil (23), corn steep liquor, glucose
(6), molasses (24), whey (25) have been tried for ribofla-
vin production. Stahmann et al. (21) reported riboflavin
yields in excess of 15 g/L of culture broth in a sterile
aerobic submerged fermentation of Ashbya gossypii with
a nutrient medium containing molasses or plant oil as
major carbon source. Ertrk et al. (25) studied fermenta-
tive production of riboflavin by Ashbya gossypii in a medium
containing whey. The quantities of riboflavin produced
by Ashbya gossypii in whey with different supplements
like bran, glycine + peptone, sucrose, glycine, yeast ex-
tract, peptone, and soybean oil were 389.5, 120, 87.5, 78.3,
68.4, 23.2, and 17.5 mg/L, respectively.
Industrial waste material like activated bleaching
earth (waste discharged from an oil refinery plant) (23)
and agroindustrial byproducts like grape must, beet mo-
lasses and peanut seed cake (26) have also been used for
the production of riboflavin. When waste activated bleach-
ing earth containing 40 % palm oil was used for ribofla-
vin production by Ashbya gossypii, the riboflavin concen-
tration reached 2.1 g/L in 10 days. This concentration
was almost 1.5 times higher than for cultures grown on
pure palm oil (23). Riboflavin production in a culture of
Ashbya gossypii was enhanced by 1.6 times after 4 days
(2.5 g/L) with the addition of 1 % mineral support with
adsorbed soybean oil to the medium (27).
Kalingan and Liao (28) determined the effect of var-
ious low cost organic wastes as flavinogenic factors and
the various concentrations at which they induced flavi-
nogenecity resulting in higher yields of riboflavin. Or-
ganic wastes like beef extract, hog casings, blood meal
or fish meal supported the production of riboflavin from
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Fig. 1. Structure of menaquinone (MK-n)
Eremothecium ashbyii NRRL 1363. Carbon source at 50 g/L
(dextrose equivalents) of molasses and nitrogen source
at 50 g/L of peanut seed cake were found to be optimal
levels to yield higher riboflavin.
Fermentation using Bacillus subtilis. Riboflavin bio-
synthesis was studied in Bacillus subtilis using classical
genetics and r-DNA technology. Cloning and DNA nu-
cleotide sequencing indicated that enzymes required for
biosynthesis of riboflavin are encoded by gene organiza-
tion as a single 4.3 kb operon. Gene amplification and
substitution of wild type promoters and the regulatory
regions with strong constitutive promoter from Bacillus
subtilis phage SPO 1 have resulted in increased ribofla-
vin production (29). The B. subtilis riboflavin-producing
strain developed by Perkins et al. (30) contains multiple
copies of a modified B. subtilis riboflavin biosynthetic
operon (rib operon) integrated at two different sites in
the B. subtilis chromosome. The modified rib operons are
expressed constitutively from strong phage promoters
located at the 5’ end and in an internal region of the
operon. The engineered strain also contains purine ana-
logue-resistant mutations designed to deregulate the pu-
rine pathway and a riboflavin analogue-resistant muta-
tion in ribC that deregulates the riboflavin biosynthetic
pathway.
One of the proteins encoded by the riboflavin ope-
ron of Bacillus subtilis, RibA, is the rate-limiting enzyme
in an industrial riboflavin producing strain. Humbelin et
al. (31) introduced an additional single copy of the ribA
gene into the sacB locus of the riboflavin production
strain, and expressed constitutively from the medium
strength vegI promoter. This led to improved riboflavin
titers and yields of riboflavin on glucose of up to 25 %.
Recently, Nippon Roche, Japan, has developed and
commercialized a single step fermentative riboflavin pro-
duction using a recombinant Bacillus subtilis strain, which
effectively produces riboflavin directly from glucose in
fed-batch operation (6). In order to maintain operational
stability and low operating cost, computerized control
of the fed-batch cultivation is considered desirable. Ho-
riuchi and Hiraga (6) described the industrial applica-
tion of a fuzzy control system to large-scale recombinant
riboflavin production. The system was applied to the on-
-line control of the feed rate and the pH of the fed-batch
culture for the fermentative production of riboflavin.
Fuzzy control system has successfully operated a large-
-scale main fermentor. The operational results showed
that the system was able to automate the operation
based on the information gained from the operators and
to improve both the process productivity and the opera-
tional stability in commercial scale production.
Fermentation using Corynebacterium ammoniagenes.
Improved strains for the production of riboflavin were
constructed through metabolic engineering using recom-
binant DNA techniques in Corynebacterium ammoniagenes.
In order to increase the expression of biosynthetic genes,
DNA fragments that had promoter activities in C. ammo-
niagenes were isolated. When the DNA fragment (P54-6)
showing the strongest promoter activity in minimum me-
dium was introduced into the upstream region of the ri-
boflavin biosynthetic genes, the accumulation of ribofla-
vin was elevated 3-fold. In that strain, the activity of GTP
cyclohydrolase II, the first enzyme in riboflavin biosyn-
thesis was elevated 2.4-fold, whereas that of riboflavin
synthase, the last enzyme in the biosynthesis, was ele-
vated 44.1-fold. Changing the sequence containing the
putative ribosome-binding sequence of 3,4-dihydroxy-2-
-butanone-4-phosphate synthase/GTP cyclohydrolase II
gene led to higher GTP cyclohydrolase II activity and
strong enhancement of riboflavin production. Through-
out the strain improvement, the activity of GTP cyclohy-
drolase II correlated with the productivity of riboflavin.
In the highest producer strain, riboflavin was produced
at the level of 15.3 g/L after 72 h in a 5-litre jar fermen-
tor without any end product inhibition (32).
Fermentation using Lactococcus lactis. Sybesma et
al. (33) developed Lactococcus lactis strain using both di-
rect mutagenesis and metabolic engineering for simulta-
neous overproduction of both folate and riboflavin. The
Lactococcus lactis MG 1363 was exposed to riboflavin an-
alogue roseoflavin. The roseoflavin resistant strain (Lac-
tococcus lactis CB010) showed a deregulated riboflavin bio-
synthesis resulting in riboflavin production instead of ri-
boflavin consumption. Lactococcus lactis CB010 was then
transformed with pNZ7010 expressing the gene folKE
that codes for the bifunctional protein 2-amino-4-hydro-
xy-6-hydroxymethyl dihydropteridine pyrophosphoki-
nase and GTP cyclohydrolase I. This resulted in more
than 10-fold increase in extracellular folate level, and
more than 2-fold increase in total folate level.
Miscellaneous. Another industrial method for the
production of riboflavin is based on microbial produc-
tion of D-ribose, which then serves as starting material
for further chemical synthesis of riboflavin. This chemi-
cal conversion process requires multiple steps, and is
time consuming resulting in higher costs as compared to
direct production by fermentation.
Downstream processing of riboflavin
Riboflavin is recovered from the broth by centrifu-
gation after inactivation of the microorganisms by heat.
Pasteurization of the broth ensures that no viable cells of
the production organism are present in the final prod-
uct. After heating, the cell mass is separated from fer-
mentation broth by centrifugation. Differential centrifu-
gation leads to separation of cells and riboflavin crystals
because of differences in size and sedimentation behav-
iour. Riboflavin is then recovered from cell-free broth by
using evaporation and vacuum drying.
Vitamin B12
One of the most interesting and fascinating mole-
cules in the world of science and medicine is vitamin B12
(cobalamin), which was originally discovered as the
anti-pernicious anemia factor in the early 1920s, when
two American physicians, Minot and Murphy, demon-
strated it to cure pernicious anemia, a disorder first de-
scribed in 1835, with a diet that included raw liver. In
humans, the vitamin is required in trace amounts (ap-
proximately 1 mg/day) to assist the action of only two
enzymes, methionine synthase and (R)-methylmalonyl-
-CoA mutase; yet commercially more than 10 t of B12 are
produced each year from a number of bacterial species.
The term vitamin B12 is widely used to describe com-
pounds of the cobalamin group. Natural forms are ade-
nosylcobalamin, methylcobalamin and hydroxocobala-
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min. Cyanocobalamin, by definition vitamin B12, is the
industrially produced stable cobalamin form which is
not found in nature (34, Fig. 2). Vitamin B12 is obtained
exclusively by fermentation process. It is produced by a
number of pharmaceutical companies to meet annual
demands worldwide. Merck began production of vita-
min B12 by Pseudomonas denitrificans in 1952 and have
improved the efficiency of culture more than 30-fold rel-
ative to the performance of the original soil isolates by
genetic manipulations and microbial screening (7). At
first, vitamin B12 for human therapy and as a food or
feed supplement was obtained as a byproduct of Strep-
tomyces antibiotic (neomycin, chlortetracycline) fermen-
tation. Good strains were also isolated from manure and
sewage sludge. Mutagenic treatments have resulted in
improved activity, but in all cases cobalt ions and 5,6-
-dimethylbenzimidazole (5,6-DMBI) have to be added in
addition to the precursors such as glycine, threonine,
and aminopropanol (29). During the past two to three
decades, several microorganisms have been employed
for the efficient production of vitamin B12. The list of va-
rious microorganisms producing vitamin B12 and the re-
spective yields are reported by Martens et al. (35, Table 2).
Biosynthetic pathway of vitamin B12
Vitamin B12 biosynthesis is restricted to microorgan-
isms. Most of the steps in the biosynthesis of vitamin B12
have been characterized in Pseudomonas denitrificans, Sal-
monella typhimurium and Propionibacterium freudenreichii.
Roth et al. (36) reported about the requirement of more
than 30 genes for the entire de novo biosynthesis of co-
balamin, which amounts to about 1 % of a typical bacte-
rial genome. Two different biosynthetic routes for vita-
min B12 exist in nature:
• aerobic, or more precisely an oxygen-dependent path-
way that is found in organisms like P. denitrificans,
and
• anaerobic, oxygen-independent pathway investigated
in organisms like P. shermanii, Salmonella typhimurium
and Bacillus megaterium.
Genes encoding enzymes contributing to the oxygen-
-dependent cobalamin biosynthesis are recognized by the
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Fig. 2. Structure of vitamin B12
Table 2. Species of microbial producers and microbiological processes recommended for the production of vitamin B12
Species of microorganism Main component of
culture medium
Conditions of fermentation Vitamin B12
production/(mg/L)
Propionibacterium freudenreichii Glucose Anaerobiosis, 5,6-dimethyl benzimidazole 206.0
Rhodopseudomonas protamicus Glucose 5,6-dimethyl benzimidazole 135.0
Propionibacterium shermanii Glucose 5,6-dimethyl benzimidazole 60.0
Pseudomonas denitrificans Sucrose Aerobiosis, betaine 60.0
Nocardia rugosa Glucose Aerobiosis 18.0
Rhizobium cobalaminogenum Sucrose Aerobiosis 16.5
Micromonospora sp. Glucose 5,6-dimethyl benzimidazole 11.5
Streptomyces olivaceus Glucose 5,6-dimethyl benzimidazole 6.0
Nocardia gardneri Hexadecane Aerobiosis 4.5
Butyribacterium methylotrophicum Methanol Anaerobiosis 3.6
Pseudomonas sp. Methanol 5,6-dimethyl benzimidazole 3.2
Arthrobacter hyalinus Isopropanol 5,6-dimethyl benzimidazole 1.1
prefix cob, while genes involved in the oxygen-indepen-
dent pathway are usually named using the prefix cbi. A
schematic outline of cobalamin biosynthesis and its oxy-
gen-dependent versus oxygen-independent differences are
shown in Fig. 3.
The biosynthesis of all tetrapyrrole derivatives starts
from the C-5 skeleton of glutamate. In the first step,
tRNA-bound glutamate is reduced to glutamate-1-semi-
aldehyde by glutamyl-tRNA reductase. The aldehyde is
converted in a second step via an intramolecular shift to
form 5-aminolevulinic acid. Two molecules of 5-aminole-
vulinic acid are condensed to generate porphobilinogen
molecule. Four porphobilinogen molecules are polymer-
ized, rearranged and then cyclized to form uroporphyri-
nogen III, the first macrocyclic intermediate (35). Whilst
decarboxylation of uroporphyrinogen III leads to the
biosynthesis of hemes and chlorophylls, methylation of
uroporphyrinogen III at C-2 and C-7 results in the syn-
thesis of precorrin-2, a dimethylated dipyrrocorphin that
is also the last common intermediate in the synthesis of
coenzyme F430 and siroheme. The methyl groups added
to the tetrapyrrole framework are derived from (S)-ade-
nosyl-L-methionine; and the two methyl groups are ad-
ded by the action of methyltransferase, which is able to
catalyze the addition to both positions (37,38). At pre-
corrin-2, the two pathways for cobalamin biosynthesis
diverge (39): in the aerobic pathway, precorrin-2 is meth-
ylated at C-20 by a further methyltransferase to give
precorrin-3A, while in the anaerobic pathway, precor-
rin-2 is chelated with cobalt to give cobalt-precorrin-2, a
reaction which is catalyzed in S. enterica by CbiK (40).
Thus, the oxygen-dependent and independent pathways
for B12 synthesis are quite distinct: the oxygen-independ-
ent part of the pathway starts with the insertion of co-
balt into precorrin-2, while this chelation reaction in the
oxygen-dependent part occurs only after nine previous
reaction steps. Interestingly, the two cobalt-chelatases
employed for these reactions are different in that the ox-
ygen-dependent pathway chelatase requires ATP, in con-
trast to its anaerobic counterpart, which requires no
high-energy equivalents.
A further difference between the two routes is the
method employed to promote the ring-contraction pro-
cess, with the removal of C-20 from the ring. Under aer-
obic conditions, the C-20 atom of precorrin-3A is oxi-
dized by molecular oxygen, sustained by a Fe4S4 cluster
containing protein (CobG), with the subsequent release
of C-20 as acetate. Under anaerobic conditions, the ring
contraction process is likely to be mediated via the com-
plexed cobalt ion with its ability to assume different va-
lence states (+1 to +3) to assist in the oxidation, resulting
in the release of C-20 as acetaldehyde.
While the B12 biosynthetic pathways diverge at pre-
corrin-2, they do join again at the level of adenosylco-
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Fig. 3. Schematic representation of the aerobic and anaerobic cobalamin biosynthetic pathways (35)
byric acid, which is converted into cobinamide by the
attachment of an aminopropanol arm to the propionic
acid side-chain of the ring D. The lower nucleotide loop
is attached by transferring the phosphoribosyl residue of
nicotinic acid mononucleotide to DMBI. The resulting
a-ribozole is finally covalently linked to GDP-activated
adenosylcobinamide, thereby releasing GMP and giving
rise to the completely manufactured coenzyme B12 mole-
cule.
Fermentative production of vitamin B12 using
Propionibacterium sp.
It has been demonstrated that Propionibacteria spe-
cies has the highest potential to accumulate vitamin B12
intracellularly. Propionibacterium shermanii and Propioni-
bacterium freudenreichii are most widely used. Propioni-
bacteria produce vitamin B12 intracellularly and excrete
mainly propionic acid and acetic acid extracellularly. All
Propionibacterium strains employed for vitamin B12 pro-
duction are microaerophilic and produce vitamin B12 in
high yields only under very low oxygen concentrations.
However, the biosynthesis of DMBI requires oxygen.
Therefore, the bioprocess of vitamin B12 production using
Propionibacterium strains is divided into two stages. In
the first three days of fermentation, the bacteria are
grown anaerobically to produce the vitamin B12 precur-
sor cobamide, a vitamin B12 intermediate missing the
DMBI moiety. Subsequently, vitamin B12 formation is
completed by gentle aeration of the whole culture for
1–3 days, allowing the bacteria to undertake the oxygen
dependent synthesis of the DMBI and to link it to co-
bamide. Furthermore, it is crucial to neutralize the accu-
mulated propionic acid during the whole fermentation
process in order to maintain the production culture at
pH=7. Propionic acid amounts to 10 % of the fermenta-
tion volume (41).
Quesada-Chanto et al. (42) optimized the production
of propionic acid and vitamin B12 by using Propionibac-
terium acidipropionici NRRL B3569 in continuous culture.
Their investigations showed that within a concentration
range of 30–170 g/L of sucrose in the fermentation me-
dium, no significant substrate inhibition occurred. In the
optimization of the pH value, temperature, and aeration,
it was established that the conditions for propionic acid
production and vitamin B12 production are different.
Whereas the optimal production of propionic acid took
place under completely anaerobic conditions with a pH
value of 6.5 and temperature of 37 °C, optimal vitamin
B12 production required a temperature of 40 °C and aer-
obic conditions (0.5 vvm aeration at 100 rpm) with a pH
value of 6.5.
Marwaha et al. (7) have studied the role of amino
acids, betaine and choline in vitamin B12 biosynthesis by
the three strains of Propionibacterium, viz. P. shermanii 566,
P. shermanii and Propionibacterium arl AKU 1251. They
supplemented whey permeate medium with eleven ami-
no acids (0.05 %, by mass per volume). Betaine hydro-
chloride and choline chloride at mass per volume ratios
of 0.25, 0.50 and 0.75 % were evaluated. Of the eleven
amino acids tested, L-glutamic acid promoted both growth
and product formation to a maximum in all three strains.
Betaine was found to be better stimulator than choline.
The stimulatory effect of betaine and choline on vitamin
B12 synthesis in strains of Propionibacterium sp. may be
explained similarly to the case of Pseudomonas denitrifi-
cans, i.e. the compounds do not need to be metabolized
to be stimulatory and may not even need to enter the
cell to exert their influence on product formation.
Marwaha and Sethi (43) utilized dairy waste for the
production of vitamin B12. Propionibacterium shermanii 566
synthesized 5.76 mg of vitamin B12 per litre of whey con-
taining 4 % lactose supplemented with 0.5 % (NH4)2HPO4
when fermentation was carried out at 30 °C under an-
aerobiosis for the first half (84 h) followed by aerobiosis
for the second half of the fermentation (84 h). The me-
tabolite started accumulating at the end of the maxi-
mum growth phase (4th day) and lasted until the curve
reached a plateau (7th day). Growth of P. shermanii 566
also reduced the biochemical oxygen demand (BOD) of
the whey by >90 %, thereby decreasing the BOD of the
milk plant effluents. The vitamin B12-enriched fermented
whey was found to replace the animal protein factor
(APF) as a vitamin B12 source in poultry rations. There-
fore, the technology developed is a worthwhile attempt
to utilize whey for vitamin B12 production and, in turn,
reduce the water pollution problem. The same authors
(44) simulated the fermentation conditions for vitamin
B12 biosynthesis from whey. The observed results and
simulated expected values obtained by fitting statistical
equations to the recorded data showed that 24-hour-old
inoculum, c(iron)=5 mg/L and 4 % whey lactose were
optimal for vitamin B12 biosynthesis when fermentation
was carried out under anaerobic (84 h) and aerobic (84 h)
conditions at 30 °C. The supplementation of whey me-
dium with 0.5 % (NH4)2PO4 further enhanced the me-
tabolite yield. P. shermanii under optimal cultural condi-
tions was found to be better than Propionibacterium arl
AKU 1251 in fermenting whey lactose for product for-
mation.
Yongsmith and Chutima (45) studied the production
of vitamin B12 by living bacterial cells immobilized in
calcium alginate gels. Whole viable cells of Propionibacte-
rium sp. strain arl AKU 1251 were immobilized in calci-
um alginate gels. The vitamin B12 production and growth
of immobilized cells could be increased by incubation of
the entrapped cells in a medium containing high con-
centrations of carbon and nitrogen sources. The presence
of precursors of vitamin B12, namely cobaltous sulphate
and 5,6-dimethyl benzimidazole, together with surfac-
tant Tween 80, at optimum concentrations markedly en-
hanced the vitamin B12 production, the maximum yield
reaching as high as 20 mg/L of medium.
For enhanced production of vitamin B12, random mu-
tagenesis has been used to generate the mutant strains
producing vitamin B12 in high yield. In general, a high
yield of vitamin B12 has been achieved by treating the
microorganisms with mutagenic agents such as UV light
or chemical reagents and selecting the strains with prac-
tical advantages, such as genetic stability, reasonable
growth rates and resistance to high concentrations of
toxic intermediates present in the growth medium (35).
Advances in the molecular biology and biochemistry re-
lated to the biosynthesis of vitamin B12 have led to the
isolation of several enzymes responsible for the synthe-
sis of vitamin B12. Piao et al. (46) studied vitamin B12
production in genetically engineered Propionibacterium
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freudenreichii. They described the expression of various
genes that are required for the biosynthesis of vitamin
B12 from d-amino-levulinic acid (ALA). The results showed
increased production of vitamin B12 in genetically engi-
neered Propionibacterium freudenreichii.
The production of tetrapyrrole compounds and vita-
min B12 by using genetically engineered Propionibacterium
freudenreichii has been overviewed by Murooka et al. (47).
They have reviewed the advancement of genetic engi-
neering in P. freudenreichii in recent years, covering the
molecular aspects of the formation of tetrapyrrole com-
pounds and vitamin B12.
Problems associated with the production of vita-
min B12. The major problem in vitamin B12 production
using Propionibacterium is the growth inhibition of the
cell due to the accumulation of inhibitory metabolites
such as propionic acid and acetic acid (48). Ken-ichiro et
al. (49) studied various approaches of controlling the
concentrations of propionic acid at low level as follows:
a) the periodic cultivation of Propionibacterium where
dissolved oxygen (DO) concentration was alterna-
tively changed between 0–1 ppm,
b) cell recycle system using hollow fiber module,
c) mixed culture using Propionibacterium and Ralstonia
eutropha where the latter microorganism assimilates
the propionic acid produced by the former.
It was found that the productivity of vitamin B12
was highest using the cell recycle system, while if the
performance was evaluated based on the amount of vi-
tamin B12 produced per unit volume of the medium
used, the mixed culture system gave the highest value.
Performance of Propionibacterium freudenreichii in an-
aerobic, aerobic and periodic fermentations was studied.
It was found that oxygen is a key to the metabolic regu-
lation. Cells could grow faster during a shorter period (6
h) after a DO-shift. However, long time aerobic fermen-
tation (over 6 h) is disadvantageous in cell growth due
to the inhibititory effect of oxygen on the synthesis of
cytochromes. The propionate was decomposed immedi-
ately and pyruvate was accumulated after the DO-shift.
Low DO was found to be advantageous in cell growth,
in decomposition of propionate, and in lowering the
production of acetate. A novel cyclic operation where
anaerobic and aerobic conditions were alternatively im-
plemented was developed advantageously in order to
enhance the production of vitamin B12 (50).
Fermentative production of vitamin B12 using
Pseudomonas dinitrificans
Pseudomonas dinitrificans growth parallels cobalamin
synthesis under aerobic conditions, if the culture is di-
rectly supplemented with 5,6-DBIM and cobalt salts.
Maintaining low DO has a favourable effect. Several vi-
tamin B12 derivatives can be produced either by direct
fermentation or by chemical conversion of cyanocobala-
min. The culture is aerated during the whole fermenta-
tion process of about 2–3 days at 30 °C and pH values
are maintained at 6–7.
The amplification of the eight genes in the cobF–cobM
operon in P. denitrificans and of the cobA and cobE genes
resulted in the increased production of vitamin B12. The
term 'amplification' is used to describe an increase in
gene copy number by the use of multicopy plasmids. In
P. denitrificans, a 30 % increase in cobalamin production
was detected, caused by amplification of the cobF–cobM
gene cluster. An additional productivity enhancement of
20 % was achieved by increasing the cobA and cobE copy
number. The heterologous expression of the corA gene
from Methanobacterium ivanovii, encoding an enzyme de-
void of substrate inhibition and bluB, bluE and bluF
genes from Rhodobacter capsulatus, is suggested to over-
come the substrate inhibition of the cobA-encoded me-
thyltransferase, which catalyzes the first dedicated steps
of vitamin B12 biosynthesis (51). Cellular DMBI biosyn-
thesis was significantly enhanced by trans-expression of
the bluB gene of R. capsulatus (52). Stimulation of vita-
min B12 production by (R)-1-amino-2-propanol and
O-phospho-L-threonine, a new intermediate assumed to
take the place of (R)-1-amino-2-propanol in the forma-
tion of the nucleotide loop of vitamin B12, was also de-
tected. The positive effects of O-phospho-L-threonine on
vitamin B12 production were also achieved by trans-ex-
pression of the bluE and bluF genes of R. capsulatus (52).
Miscellaneous
The formation of B vitamins (nicotinic acid and ni-
cotinamide, thiamine, vitamin B6 and vitamin B12) dur-
ing the soaking of soybeans by bacteria, isolated from
tempeh, was investigated (53). Among the isolates ex-
amined, no vitamin B6 producer was found. After inocu-
lation of the soaking soybeans with Citrobacter freundii,
Klebsiella pneumoniae, Pseudomas fluorescens and Strepto-
coccus sp. the concentrations of vitamin B12 increased
significantly. For the first time it was found that soak-
ings inoculated with C. freundii showed an increased vi-
tamin B12 content. Nicotinic acid and nicotinamide were
produced by Lactobacillus spp. and C. freundii. The latter
synthesized thiamine as well.
Methanogens are also reported to be used for the
production of vitamin B12 (54,55). Vitamin B12 produc-
tion by methanogens may have following advantages
over conventional vitamin B12 producers:
• the concentration of the vitamin B12 in the broth is
ten times greater than that using propionic acid uti-
lizing microbes;
• the main product, methane, does not inhibit growth
of methanogens and could provide a high cell den-
sity culture system;
• methanol, CO2 and acetic acid used as substrates are
inexpensive, relatively stable and renewable.
However, long residence times are required for the
substrate because methanogens grow more slowly than
aerobic microbes, and this makes the fermentation facil-
ity larger. Zhang et al. (55) studied biogas fermentation
from alcohol waste fluid to evaluate the anaerobic diges-
tion process and the production of vitamin B12 as a by-
product. Anaerobic digestion using acclimated methano-
gens was performed using the continuously stirred tank
reactor (CSTR) and fixed-bed reactor packed with rock
wool as carrier material at 55 °C. They also studied the
effects of metal ions added to the culture broth on meth-
ane and vitamin B12 formation. Vitamin B12 production
was 2.92 mg/L in the broth of the fixed-bed reactor, and
twice that in the CSTR. Yang et al. (54) studied continu-
ous methane fermentation and the production of vita-
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min B12 in a fixed reactor packed with loofah. Loofah
carrier immobilized almost 95 % of the methanogens,
which led to the more effective bioreaction. Fermenta-
tion using CO2/H2 acclimated methanogens was con-
ducted in a jar fermentor with hydraulic reaction times
(HRTs) of three and six days. With an HRT of three
days, methane production rate and vitamin B12 concen-
tration in the culture broth and liquid were 6.18 L/L/h
and 2.88 mg/L, respectively; these values were 11.96
L/L/h and 37.54 mg/L in the HRT of six days.
A continuous fermentation of extracellular vitamin
B12 compounds was attempted by Mazumder et al. (56)
using a diatomaceous clay fixed–bed reactor. They used
Methanosarcina bakeri for the production of vitamin B12
using methanol as the substrate.
Inoue et al. (57) reported the production of vitamin
B12 by Acetobacterium sp. and its tetrachloromethane re-
sistant strains. Of the 800 isolates, a strictly anaerobic
bacterium, tentatively designated as 69, isolated from
sea sediment was selected and used for the studies. The
isolate grown on methanol produced 11 mg of cyano-
cobalamin per gram of dry cells after 7-day cultivation.
Tetrachloromethane resistant strains were obtained by
ethylmethanesulphonate treatment, and they produced
23 mg of cyanocobalamin per gram of dry cells in the
presence of 10 mM tetrachloromethane.
Bainotti et al. (58) studied the kinetics of the inhibi-
tion of substrate and product on the growth of the ace-
togen (Acetobacterium sp.) in a defined medium with
methanol and CO2. They also modified the medium
composition in order to achieve the best growth yield
for Acetobacterium sp. in batch culture using different
concentrations of nutrients in the basal medium. They
reported the highest production of 4.84 mg/L of coba-
lamin with the modified medium (supplemented with
2 g/L of yeast extract) as compared to 2.21 mg/L with
basal medium (supplemented with 0.4 g/L of yeast ex-
tract) and 3.19 mg/L with synthetic medium (without
yeast extract).
Recovery of vitamin B12
The study of separation and purification processes
of the fermentation products is most important for their
commercial success. Recovery and purification of high
value bioproducts from their crude sources involve vari-
ous steps (extraction, membrane filtration, and sorp-
tion), which lead to low overall yields. Conventional
chromatographic and chemical processes are capital and
energy consuming due to a number of post- and pre-
treatment steps involved in a processing scheme. A rapid
and selective mode of recovery of the target molecule
from the crude feedstock can prove highly advantageous
in improving the product yields and thus reducing the
overall cost of downstream processing. Adsorptive sepa-
rations are often used in the downstream processing
using various interactions, e.g. ionic, hydrophobic, affin-
ity, etc. for the recovery of biomolecules, namely antibi-
otics and vitamins.
The steps in the downstream processing for the re-
covery of vitamin B12 are summarized in Fig. 4. The bio-
mass is separated by centrifugation to obtain a cell mass
concentrate, which is then dried. Alternatively, the entire
contents of the fermentor can be concentrated or spray
dried. Cell lysis by heating the centrifuged cell mass in
an aqueous solution, or by other methods to get corri-
noids, can be used. Corrinoids are converted to vitamin
B12 or cyanocobalamin by the addition of potassium cya-
nide, usually in the presence of sodium nitrite and heat.
The vitamin solution is clarified subsequently by filtra-
tion, treatment with zinc chloride, and then precipitated
out by the addition of tannic acid or cresol to give the
product of 80 % purity, which is suitable for use as ani-
mal food additive. For greater purity, which is required
for pharmaceutical use, the clarified solution is extracted
with organic solvents, such as carbon tetrachloride, and
then with water and butanol, followed again by organic
solvents. In addition, adsorption processes such as on ion
exchangers, aluminium oxide, or activated carbon can
be used. Pure vitamin B12 can be obtained by crystalliza-
tion after the addition of organic solvents, such as phe-
nol and water.
Ramos et al. (59) studied the adsorption of vitamin
B12 from aqueous solution on non-ionic polymeric ad-
sorbents from the point of view of modelling and exper-
iments. Adsorption equilibrium isotherms and intrapar-
ticle effective diffusivities were measured in batch and
continuous stirred tank adsorbers, respectively. The pa-
rameters obtained were introduced in a model to predict
the breakthrough curves in fixed bed experiments.
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Fig. 4. Downstream processing of vitamin B12
Ascorbic acid
L-ascorbic acid is an important metabolite for most
living organisms. In humans, it is necessary for different
physiological functions and thus is an essential nutrient
(60). Deficiency in vitamin C leads to the disease scurvy
due to the role of the vitamin in the post-translational
modification of collagens. The most important function
of ascorbic acid is to protect tissue from harmful oxida-
tive products (61).
L-ascorbic acid finds its use mainly in food industry,
being a vitamin as well as an antioxidant. Approxima-
tely 50 % of synthetic ascorbic acid is used in vitamin
supplements and pharmaceutical preparations. Because
of its antioxidant properties and its potential to stimu-
late collagen production, it is also widely used as an ad-
ditive to cosmetics (62). The current global market of
L-ascorbic acid is in excess of US$ 585 million with an
annual growth rate of 3 % (63).
At present the majority of commercially manufac-
tured L-ascorbic acid is synthesized via Reichstein pro-
cess using D-glucose as a starting material (Fig. 5). Some
processes using bioconversions have been described, but
until now, due to low yields obtained, they have not
been developed (64). Reichstein process involves six
chemical steps and one fermentation step for oxidation
of D-sorbitol to L-sorbose. Overall yield of L-ascorbic
acid from D-glucose obtained by Reichstein process is
~50 %. It is highly energy consuming since it requires
high temperature and/or pressure for many steps. In
addition, most of the chemical transformations involve
considerable quantities of organic and inorganic sol-
vents and reagents like acetone, sulphuric acid and so-
dium hydroxide. Due to these aspects, straight environ-
mental control of the process is required, resulting in
significant waste disposal cost. These economical factors
have generated substantial interest in exploitation of mi-
crobial biotransformation in the manufacturing of L-as-
corbic acid (3,29). Recent innovations in fermentation
processes and advances in biochemistry and recombi-
nant DNA technology widen the options available for
exploitation of biotechnology in L-ascorbic acid produc-
tion (65).
Bacterial fermentation processes
At present there are six bacterial fermentation pro-
cesses for the production of 2-keto-L-gulonic acid, a di-
rect precursor of L-ascorbic acid (3). Different pathways,
named after one of the metabolic intermediates are sor-
bitol pathway, L-idonic acid pathway, L-gulonic acid path-
way, 2-keto-D-gluconic acid pathway, 2,5-diketo-D-gluco-
nic acid pathway, and 2-keto-L-gulonic acid pathway.
These are all summarized in Fig. 6. The most commer-
cially advanced methods are the oxidation of D-sorbitol
or L-sorbose to 2-keto-L-gulonic acid (2-KLG) via the in-
termediate L-sorbosone (sorbitol pathway), and the oxi-
dation of D-glucose to 2-keto-L-gulonate via D-gluconic
acid, 2-keto-D-gluconic acid and 2,5 diketo-D-gluconic
acid (2-keto-D-gluconic acid pathway) (4).
Sorbitol pathway. Sorbitol is transformed by fer-
mentation to 2-KLG via the intermediate L-sorbosone.
Transformation is performed by several strains of genera
Pseudomonas and Acetobacter, which catalyse the oxida-
tion of L-sorbose (and/or D-sorbitol) to 2-KLG via a se-
ries of membrane-bound dehydrogenases, leading to the
formation of L-sorbosone (66). The final oxidation to
2-KLG is catalyzed by either membrane-bound (67) or
cytosolic sorbosone dehydrogenases (68), depending on
the strain. Sugisawa et al. (69) isolated cultures of G.
oxydans that produced up to 60 g/L of 2-KLG from
L-sorbose or D-sorbitol, with 60 % conversion.
Genetic engineering has also been used in strain im-
provement to enhance yield via D-sorbitol pathway (66).
Glucanobacter oxydans is the species of choice for this
purpose but the subcellular (cytosolic or membrane-
-bound) location of dehydrogenase required for the con-
version of D-sorbitol to 2-KLG varies from strain to
strain. Transfer of D-sorbitol pathway intermediates into
the cytoplasm of these strains is detrimental owing to
the presence of cytosolic reductase, which channels in-
termediates in the pentose phosphate cycle. To overcome
this problem, membrane-bound dehydrogenases from
alternative sources have been expressed in recombinant
Glucanobacter oxydans to complement or replace cytosolic
enzymes. For example, from IFO 12258 of Acetobacter li-
quefaciens strain membrane-bound sorbosone dehydroge-
nase was expressed in the OX4 strains of Glucanobacter
oxydans, which had membrane-bound sorbitol dehydro-
genase and sorbose dehydrogenase but not cytosolic de-
hydrogenase. Significant yield improvements of 2-KLG
from both L-sorbose (68 to 81 %) and L-sorbosone (23 to
83 %) were observed in resulting strains but there were
no yield improvements under fermentation conditions (68).
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Fig. 5. The Reichstein process for L-ascorbic acid production
Saito et al. (70) isolated Glucanobacter oxydans G624,
which could convert D-sorbitol to L-sorbose almost quan-
titatively via a membrane-bound sorbitol dehydrogenase,
but was unable to synthesize 2-KLG. Membrane-bound
sorbose dehydrogenase and cytosolic sorbosone dehy-
drogenase were cloned from Glucanobacter oxydans T-100,
a strain that can produce 2-KLG, and expressed in Glu-
canobacter oxydans G624. After optimization of the expres-
sion system, a chemical mutagenesis to block further
2-KLG metabolism resulted in a Glucanobacter oxydans
strain which provided more than 85 % yield of 2-KLG.
2-keto-D-gluconic acid pathway. In this pathway,
D-glucose is transformed to 2-KLG via D-gluconic acid,
2-keto-D-gluconic acid and 2,5-diketo-D-gluconic acid
(2,5-DKG). Until now no bacterial strains capable of effi-
ciently catalyzing the complete conversion of D-glc to
2-KLG have been isolated. This is carried out in three
main steps; each step is carried out by using different
microorganisms (3): (i) transformation of D-glucose to
2-keto-D-gluconic acid: the transformation of glucose to
2-keto-D-gluconic acid is carried out by Acetobacter mela-
nogenus (71) and Pseudomonas albosesamae (72). Some Ace-
tobacter strains also synthesize 2-keto-D-gluconic acid;
(ii) oxidation of 2-keto-D-gluconic acid: this oxidation is
carried out by Bacterium hoshigaki and Bacterium gluconi-
cum with 2,5-DKG as a product. In addition, Acetomonas
albosesamae can directly transform D-glucose to 2,5-DKG;
(iii) oxidation of 2,5-DKG acid: Sonoyama et al. (73) have
described the process for conversion of 2,5-DKG into
2-KLG. The mentioned strains were of the genera Brevi-
bacterium and Pseudomonas, and maximum yield was
obtained from Brevibacterium ketosoreductum. The use of
Corynebacterium has also been suggested.
The use of mixed or sequential fermentations for con-
version of D-glucose to 2-KLG was originally exploited
by Sonoyama et al. (74) who used a mutant Erwinia strain
to convert D-glucose into 2,5-DKG. The whole culture
broth was then treated with sodium dodecyl sulphate to
reduce cell viability, mixed with glucose and then sup-
plied to a mutant strain of Corynebacterium for conver-
sion to 2-KLG. The whole process achieved yields of
2-KLG of up to 85 % from D-glucose with final 2-KLG
concentrations of 10.5 g/L. This approach improved pre-
vious methods based on the harvesting of 2,5-DKG from
the first culture broth, as up to 80 % of this unstable
compound can be lost during such a process (71).
These efforts were later superseded by the extension
of the metabolic capacity of the bacterial strain via ge-
netic engineering. Anderson et al. (75) cloned a cytosolic
2,5-DKG reductase gene from Corynebacterium sp. and
expressed it in Erwinia herbicola. The recombinant organ-
ism was capable of synthesizing 2-KLG from D-glucose
but the yields attained were very poor (1 g/L of 2-KLG
from 20 g/L of D-glucose). This was attributed to the re-
quirement for transport of intermediates between the
periplasmic space containing the three enzymes neces-
sary for the conversion of D-glucose into 2,5-DKG and
the cytoplasm containing 2,5-DKG reductase required
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Sorbitol
Fig. 6. Different pathways for transformation of glucose to 2-keto-L-gulonic acid
for 2-KLG synthesis. However, Grindley et al. (76) showed
that recombinant E. citreus expressing cytoplasmic 2,5-
-DKG reductase from Corynebacterium sp. could accumu-
late 19.8 g/L of 2-KLG with a 49 % conversion efficiency
from glucose. Such improvements in yield were attained
by optimization of the fermentation conditions, careful
selection of the promoter controlling the expression of
the 2,5-DKG reductase gene and by the use of mutant
strains of E. citreus which were unable to use 2,5-DKG
or 2-KLG for growth. Recently, a highly efficient in vitro
process for the production of 2-KLG via this route has
been established. Bioreactors were described based on
the use of an NADPH-dependent glucose dehydroge-
nase. The product of this reaction was converted to
2,5-DKG using permeabilised cells of Pseudomonas citrea
and further transformed to 2-KLG by a soluble 2,5-DKG
reductase. The glucose dehydrogenase and 2-DKG re-
ductase formed a redox couple resulting in the in vitro
regeneration of the nicotinamide cofactor. Glucose could
be converted to 2-KLG with >60 % conversion, with an
overall productivity of 2 g(2-KLG)/L/h (77).
Bioconversion of 2-KLG to L-ascorbic acid
In the conventional process, 2-KLG is converted to
L-ascorbic acid chemically via two routes. The first in-
volves multiple steps including:
• esterification of a 2-KLG derivative under strongly
acidic conditions to produce methyl 2-keto-L-gulo-
nate (MeKLG);
• reaction of MeKLG with a base to produce a metal
ascorbate salt;
• treatment of metal ascorbate salt with an acidulant
to obtain ascorbic acid.
The second route is a one-step method comprising
acid-catalyzed cyclization of KLG.
Both methods are commercially undesirable due to
the requirement for multiple chemical steps (first route),
or the use of large amounts of gaseous hydrogen chlo-
ride or requirement for very expensive process equip-
ment (second route) (65). To overcome this problem, se-
veral methods were discovered for the conversion of
2-KLG to L-ascorbic acid. Hubbs (78) used hydrolase en-
zyme to convert esters of 2-KLG to L-ascorbic acid. Simi-
larly, lactonases isolated from Zymomonas mobilis, Esche-
richia coli and Fusarium oxysporium were reported to
convert 2-KLG to L-ascorbic acid. However, the possibil-
ity of process improvement through better reactor de-
sign and enzyme improvement methods can be used to
increase the yields.
Some yeast strains like Candida blankii and Crypto-
coccus dimennae can also convert 2-KLG to L-ascorbic
acid. However, it gives very low yields with accumula-
tion of only 25 mg/mL of L-ascorbic acid in the medium
with 5 mg/mL of 2-KLG after 48 h of incubation. In
both species, mutagenesis of the catabolic pathway and
further investigation into optimum culture conditions
can improve yields (79).
Yeast based fermentation process for production
of ascorbic acid
Earlier studies had suggested yeast cells to contain
L-ascorbic acid. However, reassessment of these claims
in recent times using improved methodology has sug-
gested that yeasts do not possess an endogenous bio-
chemical pathway for the synthesis of vitamin C, but can
synthesize D-erythroascorbic acid. This compound ful-
fills similar antioxidant functions in yeast but has no an-
tiscorbutic activity (80). Yeast cells are, however, known
to accumulate L-ascorbic acid when incubated with L-ga-
lactose, L-galactono-1,4-lactone or L-galactono-1,4-lac-
tone intermediates from plants or animal pathway (81).
Mounting evidence suggests that biosynthesis of L-as-
corbic acid from this substrate in yeast occurs via the ac-
tivity of enzyme of the D-erythroascorbic acid pathway
(82). Moreover, expression of D-arabinono-1,4-lactone oxi-
dase from Saccharomyces cerevisiae in Escherichia coli can
overproduce D-erythroascorbic acid and L-ascorbic acid
when supplied with D-arabinono-1,4-lactone and D-ga-
lactono-1,4-lactone, respectively (83).
Saccharomyces cerevisiae and Zygosaccharomyces bailii
accumulate L-ascorbic acid intracellularly when incuba-
ted with L-galactose. Overexpression of the D-arabinose
dehydrogenase and D-arabinono-1,4-lactone oxidase in
Saccharomyces cerevisiae enhances this ability significantly.
In fact, the recombinant strain even gains ability to accu-
mulate L-ascorbic acid in culture media. Even better re-
sults can be obtained by overexpression of the plant en-
zyme L-galactose dehydrogenase from Arabidopsis thaliana
(84).
Production of L-ascorbic acid using algae
Skatrud and Huss (85) described the method for the
efficient production of L-ascorbic acid in algae. The me-
thod involved initial growth of Chlorella pyrenoidosa ATCC
53170 in a fermentor with a carbon source that is suffi-
cient for the cells to grow to an intermediate density. At
the depleted stage, additional carbon source was added
sequentially or continuously to maintain the carbon source
concentration below a predetermined level until the ad-
dition is terminated. This resulted in the production of
1.45 g/L of L-ascorbic acid. Euglena gracilis Z. is one of
the few microorganisms which simultaneously produce
antioxidant vitamins such as b-carotene (71 mg/L), vita-
min C (86.5 mg/L) and vitamin E (30.1 mg/L) (1).
Biotin
Biotin (vitamin H) is one of the most fascinating co-
factors involved in central pathways in pro- and eukary-
otic cell metabolism. Since its original discovery in 1901,
research has led to the discovery of the complete biotin
biosynthesis pathways in many different microbes and
much work has been done on the highly intriguing and
complex biochemistry of biotin biosynthesis. While hu-
mans and animals require several hundred micrograms
of biotin per day, most microbes, plants and fungi ap-
pear to be able to synthesize the cofactor themselves. Bi-
otin is added to many food, feed and cosmetic products,
creating a world market of 10–30 t/year. However, the
majority of the biotin sold is synthesized chemically
(Goldberg and Sternbach synthesis). Since the chemical
synthesis is linked with a high environmental burden,
much effort has been put into the development of bio-
tin-overproducing microbes. Fermentative production of
biotin has received much attention because of its poten-
tial to lower the production cost.
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Biosynthetic pathway for biotin
Biosynthetic pathway of biotin in different bacterial
strains such as Escherichia coli (86), Bacillus sphaericus (87),
Bacillus subtilis (88) and Sphingomonas sp. (89) has been
reported. Only the last step, the conversion of dethio-
biotin (DTB) into biotin, has not been enzymatically re-
solved, although Bacillus sphaericus could convert dethio-
biotin into (+)-biotin. A major contribution to the under-
standing of metabolic pathway for biotin synthesis from
pimelyl-CoA was originally described for E. coli. The
pathway of biotin passes through three intermediates,
7-keto-8-aminopelargonic acid (KAPA), 7,8-diaminope-
largonic acid (DAPA) and DTB. These intermediates are
individually or collectively referred to as vitamers or to-
tal vitamers. Biosynthetic pathway for biotin is shown in
Fig. 7. The main problem in biotin synthesis is the re-
pressive action of biotin on all biotin-synthesizing en-
zymes.
Ogata et al. (90) screened microorganisms and dem-
onstrated that the bacterium B. sphaericus, in contrast to
E. coli, can excrete significant quantities of biotin syn-
thetic pathway intermediates from precursor, pimelic
acid. Ohsawa et al. (91) and Gloeckler et al. (5) described
how B. sphaericus biotin (bio) genes have been cloned and
expressed in E. coli and bacilli. But, B. sphaericus is diffi-
cult to culture, since it seems unable to efficiently utilize
glucose as the carbon source, and ammonia as the nitro-
gen source; it rather uses complex organic molecules.
Brown et al. (92) studied the production of biotin by
recombinant strains of E. coli. They have constructed, by
means of genetic engineering, recombinant strains of E.
coli, which overproduced the vitamin. For further studies
the strain used was E. coli C268 having a bioA genotype
and plasmid pTG3410 with two expression cassettes.
They compared biotin and vitamers produced in tubes
(5 mL), Ehrlenmeyer flasks (200 mL), and 2- and 20-litre
fermentors. Various parameters influencing vitamers and
biotin formation were evaluated. The parameters were
culture scale, culture type, inoculation step, pH, temper-
ature, dissolved oxygen, medium constituent variation,
and precursor addition. They concluded that 20-litre fer-
mentor is the best for the production. Batch culture with
carbon source feed (glycerol) must be used. Casamino
acids influenced the production of vitamin, while prote-
ose peptone influenced plasmid viability. The optimum
pH and temperature conditions were 7 and 37 °C, re-
spectively. The precursor pimelic acid (300 mg/L) is not
limiting for the biotin production. However, a higher
concentration results in the formation of more vitamers,
but not in extra biotin. Fed-batch fermentation enabled
the cell dry mass to be increased by a factor of 18–50
g/L and biotin by a factor of 30–45 mg/L, a significant
gain over the values found in 2-litre fermentor.
Biotin production under limiting growth conditions
by Agrobacterium/Rhizobium HK4 transformed with a
modified Escherichia coli bio operon was studied by Shaw
et al. (93). The E. coli bio operon was modified to im-
prove biotin production by host cells as follows:
• the divergently transcribed wild-type bio operon
was reorganized into one transcriptional unit;
• the wild-type bio promoter was replaced with a
strong artificial (tac) promoter;
• a potential stem loop structure between bioD and
bioA was removed; and
• the wild-type bioB ribosomal binding site (RBS) was
replaced with an artificial RBS that resulted in im-
proved bioB expression.
The effects of the modifications on the bio operon
were studied in E. coli by measuring biotin and dethio-
biotin production, and bio gene expression with mini-
-cells and two-dimensional polyacrylamide gel electro-
phoresis. The modified E. coli bio operon was introduced
into a broad host-range plasmid and used to transform
Agrobacterium/Rhizobium HK4, which then produced 110
mg/L of biotin in a 2-litre fermentor, growing on a de-
fined medium with diaminononanoic acid as the start-
ing material. Biotin production was not growth phase
dependent in this strain, and the rate of production re-
mained high under limiting (maintenance) and zero
growth conditions.
Saito et al. (89) compared biotin production by re-
combinant Sphingomonas sp. pSP304 under various agi-
tation conditions. A complex medium containing (in
g/L): glycerol 60.0, yeast extract 30.0, casamino acids
5.0, K2HPO4 1.0, KCl 0.5, MgSO4·7H2O 0.5, FeSO4 0.22,
and tetracycline 0.01 was used, and biotin was produced
in the stationary phase after glycerol starvation. Differ-
ent impellers used were turbine blade, anchor, Max-
blend®, EGSTAR®, turbolift and screw. The maximum
production (66 mg/L) was obtained with a jar-fermentor
with turbine-blade impeller and the sintered sparger at
400 rpm. It was observed that cell morphology changed
with differing agitation conditions. Biotin production
was relatively high in slightly long rod-shaped cells but
low in elongated cells.
Conclusions
Microbial or microalgal processes for vitamin pro-
duction have many advantages compared to chemical
synthesis processes (if at all available). The products
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Fig. 7. Biosynthetic pathway of biotin (29,89)
from chemical processes are often racemic mixtures,
while fermentation or bioconversion reactions yield the
desired enantiomeric compound. In addition, advances
in biochemistry and DNA technology together with
genomic revolution have widened the options available
for the exploitation of biotechnology in vitamin produc-
tion. Furthermore, biotechnological processes and prod-
ucts generally have a positive environmental impact and
a positive appeal to people.
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